BNOX logo

Bionomics Limited American Depository Shares

BNOX

BNOX: Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.

more

Show BNOX Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recent trades of BNOX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by BNOX's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Antibody and checkpoint inhibitor combination therapy May. 23, 2023
  • Patent Title: Method for treating acute myeloid leukemia Oct. 25, 2022
  • Patent Title: Modulators of ion channel receptors and uses thereof Jul. 12, 2022
  • Patent Title: Anxiolytic compounds Mar. 23, 2021
  • Patent Title: Method of treating cancer by administering an anti-lgr5 monoclonal antibody Aug. 18, 2020
  • Patent Title: Predictive biomarkers Feb. 18, 2020
  • Patent Title: Predictive baseline biomarkers for use of vascular disrupting agents Dec. 31, 2019
  • Patent Title: Humanized antibodies that bind lgr5 Jul. 23, 2019
  • Patent Title: Salts, co-crystals, and polymorphs of an anxiolytic compound Apr. 23, 2019
  • Patent Title: Anxiolytic compounds Mar. 19, 2019
  • Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Feb. 26, 2019
  • Patent Title: Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to g protein-coupled receptor 49 (gpr49) Feb. 05, 2019
  • Patent Title: Predicting response to cancer therapy Dec. 25, 2018
  • Patent Title: Combination treatment protocol Nov. 27, 2018
  • Patent Title: Method for treating chronic lymphocytic leukemia Jun. 05, 2018
  • Patent Title: Anxiolytic compounds May. 22, 2018
  • Patent Title: Amine derivatives as potassium channel blockers Mar. 13, 2018
  • Patent Title: Crystalline form of an anxiolytic compound Sep. 12, 2017
  • Patent Title: Salts, co-crystals, and polymorphs of an anxiolytic compound Aug. 29, 2017
  • Patent Title: Antibodies that bind lgr4, their use in inhibiting neoplastic cells and in treating tumors Apr. 25, 2017
  • Patent Title: Anxiolytic compounds Feb. 21, 2017
  • Patent Title: Humanized antibodies that bind lgr5 Jan. 17, 2017
  • Patent Title: Amine derivatives as potassium channel blockers Nov. 15, 2016
  • Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors May. 24, 2016
  • Patent Title: Anti-gpr49 monoclonal antibodies Dec. 29, 2015
  • Patent Title: Methods of inhibiting solid tumor growth by administering gpr49 antibodies Dec. 29, 2015
  • Patent Title: Methods of treating cancer by administering anti-gpr49 antibodies Dec. 29, 2015
  • Patent Title: Methods for preparing naphthyridines Sep. 15, 2015
  • Patent Title: Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof Jun. 23, 2015
  • Patent Title: Small-molecules as therapeutics May. 05, 2015
  • Patent Title: Combination therapy for treating proliferative diseases Apr. 14, 2015
  • Patent Title: Anxiolytic compounds Dec. 09, 2014
  • Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors May. 06, 2014
  • Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Mar. 25, 2014
  • Patent Title: Chemical processes for the manufacture of substituted benzofurans Mar. 18, 2014
  • Patent Title: Anxiolytic compounds Dec. 24, 2013
  • Patent Title: Tubulin polymerisation inhibitors Oct. 15, 2013
  • Patent Title: Anxiolytic compounds Oct. 08, 2013
  • Patent Title: Potassium channel blockers and uses thereof Aug. 13, 2013
  • Patent Title: Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization Jun. 18, 2013
  • Patent Title: Benzofuran potassium channel blockers and uses thereof Nov. 13, 2012
  • Patent Title: Methods of identifying agents that inhibit angiogenesis Nov. 13, 2012
  • Patent Title: Anxiolytic compounds Oct. 23, 2012
  • Patent Title: Diagnostic method for epilepsy Oct. 16, 2012
  • Patent Title: Chromenone potassium channel blockers and uses thereof Jul. 10, 2012
  • Patent Title: Aryl potassium channel blockers and uses thereof Jun. 19, 2012
  • Patent Title: Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors Jun. 12, 2012
  • Patent Title: Mutations in ion channels Mar. 06, 2012
  • Patent Title: Nucleic acid encoding scn1a variant Aug. 02, 2011
  • Patent Title: Methods for the diagnosis and treatment of epilepsy May. 25, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of BNOX in WallStreetBets Daily Discussion

BNOX News

Recent insights relating to BNOX

CNBC Recommendations

Recent picks made for BNOX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BNOX

Corporate Flights

Flights by private jets registered to BNOX